Trial Exclusions May Skew RA Drug Comparisons
Nearly 40% of registry patients would have been excluded from phase 3 randomized controlled trials, with exclusion criteria distributed unevenly across drug classes.
By
Andrea Surnit
June 12, 2026
Clinical Scorecard: Trial Exclusions May Skew RA Drug Comparisons
At a Glance
Category Detail
Condition Rheumatoid Arthritis Key Mechanisms Biologic or targeted synthetic disease-modifying antirheumatic drugs Target Population Patients with rheumatoid arthritis initiating treatment Care Setting Routine care in Japan
Key Highlights
40% of patients met at least 1 trial exclusion criterion. Anemia and lymphopenia were the most common exclusion criteria. Janus kinase inhibitors showed higher remission rates compared to tumor necrosis factor inhibitors. Guideline-Based Recommendations
Diagnosis
Assess for trial exclusion criteria including prednisolone use, renal impairment, hepatic dysfunction, anemia, lymphopenia, thrombocytopenia, and low white blood cell count. Management
Monitoring & Follow-up
Monitor disease activity and treatment response using Clinical Disease Activity Index. Risks
Be aware of potential channelling bias due to differential distribution of trial exclusion criteria across drug classes. Patient & Prescribing Data
Patients with rheumatoid arthritis initiating biologic or targeted synthetic DMARDs.
Interleukin-6 inhibitors and CTLA4-Ig were more often selected among patients with anemia or organ dysfunction.
Clinical Best Practices
Related Resources & Content
